Fully human antibody is at the preclinical stage of development.

DSM Biologics and MorphoSys signed an agreement covering process development and cGMP manufacturing of MOR202. This fully human HuCAL® antibody is directed against CD38, a target for the treatment of multiple myeloma.

DSM Biologics will produce MOR202 in its cGMP facilities in Groningen, the Netherlands.

Previous articleSchering-Plough Acquires Its Joint Ventures in China
Next articleCPEX Pharmaceuticals Signs On DPT Laboratories to Produce Insulin Product